Juliet. you, joining call. you everybody, earnings our today quarter afternoon, Thank Good and for thank third us for
known me welcome to experiencing, our managing XX an her a time, transparently have years Juliet makes communicating in function. on lead a have our that publicly and investment experience to Let to we for traded her Street sector on those first Relations I relations excited moment sound And shareholder Juliet's you of to team the increase our committed you our continue her of We're to recognize that and Investor to team. to progress QuidelOrtho our community to ideal technology as our long value. expertise don't execute take choice strategy medical me normal. companies for
start we the having in that definitely CDC and recently, the a now my in Let season say separated didn't through just And that X.X%. that respiratory weekend, it is over me note over house. I this ILI are published
though least in yes, well. beginning understood I at it. are So and respiratory and heard at press I'll season be the we of technically, can forward a hope
which our revenue guidance our to progress quarter these all of third of expectations. EBITDA including and our third from there preannouncement, meet growth, of delivered was points to in the $XXX.X many adjusted on results, quarter report are geographies. Street with of I'm season to our durable QX. earlier-than-expected now million, million We're forging XX%, And margin of core in financial strength across ability respiratory $XXX continued and EBITDA to adjusted performance. up and our a the demand proof pleased sequentially our Turning and businesses ahead as path we noted
in flow, we cash $XX our third quarter, generated the of million which adjusted to is During business. free the another strength testament
another And $XXX million million we year-to-date, our will us of total $XX paid paid invest growth. We these company to down fortify balance have debt. sheet our we This in that flexibility believe down greater and long-term our give quarter, efforts debt. in
that point revenue to deliver in in times. to if trends we interesting across in businesses. confident with are no speed we're for execute coming We greater need over targets our look quarters a -- There's you diagnostic growth industry, settings ability on Recent use at the they before. as care our COVID-XX question our diagnostic the the the truth. operating of important testing fueled has are of and care near the testing. future drugs results for more news view, adoption from around trends the vaccines and about GLP-X ever rapid demand further patient new speculation our now reduction health there's nothing than In of
getting latest COVID-XX result could in higher of the a and likely forgo number higher In thus of levels testing. cases fact, to vaccines patients deciding
late available Nearly least booster only vaccine eligible U.S. mid-September. that million have Americans the X at received Health of to became the XX% Services The since Department COVID-XX get in reports opted XXXX. since shot of bivalent Americans one and Human
Americans people, a eligible While statistics XX% medical XXXX. exists, in severely population only among recognize a we while we the of will for are the shot greater in flu slowed for respiratory and we also that hope present eligible viruses to severity COVID-XX, other diseases decades reminder for spread received adoption and These these come. along technology general flu stark remain all test the just the with of that
these Turning diabetes material and and approved our not the do population testing are is business important AXC to we and use beginning very drugs only understood. renal to side long-term first, and in a effects serious remember to that portion select of impact come for expect only be with GLP-X are is our case that in it any while small, drugs obesity, -- of the
by medications or not these are covered Second, presently Medicare. private insurance
of patients under for these pocket today, simply medications financial reach. Americans patients XX must coverage on Medicare these of out income, medications pay nearly out fixed these for many and are With million
GLP-X is those a patients prescribing to drug, being X-month intervals decades. laboratory important the care the to role to and would metabolic-based order several on Prior duration for of establish remains which an where in However, test could their medication, we to the our play continue could in any this doctors journey. administered, baseline a may continue do for be patient
the remains of leading well. America. And growing unfortunately, internationally Further, than heart disease as it's cause
in longer disease, term. idea change testing. significant see not near While the that we'd we fewer in would the welcome or do be need a for heart -- affected by patients the
closer now quarter shift a at third look take Let's our performance. to
This strong will of and the COVID-XX in real pronounced QX by most prevalence is high than the early peak be flu First, prevalence longer assays high combo higher there United we while potential driven January. contributing in disease was duration. timing season, early a season in with flu aggressive were rates could early season to this the respiratory in less overall If see the XXXX growth Australia for sometime first preceded the drop-off COVID hemisphere, prioritization the the stages XXXX, prevalence November in throughout potentially converge, occur where XX to our mainly immediately demand COVID-XX rates States. translates
us Both significantly significant and became testing for more overall larger in share due our general from to for the market business competitors respiratory gains and specifically. respiratory testing
manage to a to market respiratory also play combating We're demand. have early role We of RSV given any capabilities operations others. and team's diagnostic customer in an to meet among position strong in respond positioned well upticks fluctuations our this our influenza, COVID-XX, both agility important seasonal and and seasonal
We given China I diagnostic and same on all a during care speak in detail. China. and companies wanted business by to Joe with calls. in the recent we in discuss strong recent not remain care geographic in isn't bullish QX, comments health to across our performance solid there neither China may some This their today us CEOs had surprise but the in China. investors, but are companies all to all and the it performance into numerous are geographies specifically businesses future. Frankly, earnings including will be health about
has QuidelOrtho the challenges of same challenges, as not but our are course, all others.
few a differences. are Here
VBP clinical labs. of This Beijing in Further, and lockdowns in is economy. part care And care. that because need of our health the the and volumes reasonably to technology, normal levels, stable. China ill has chemistry largely and we stat immediate who flight a quickly pricing Shanghai uses side ended, tenders dry by is affected Our when medium not technology, of subject not been the to drive have returned often driven been are and people our volume is business as by
is small, immunoassay Our speaking. in China still business relatively
our panel, that immunoassay will business. X% our Only tender. provinces Anne discussed and HCG often the XX to business are about to the hormones represent disease and respect China. in related be overall participating infectious categories these of With There
lower the a of and in saw we would The at in China. impact VBP X.XX%. in be the tender. XXXX participate less our tender business our That's rate X% we loss Assuming prices of than the that
outweigh topic. risks. been discussed Our opportunities our often far also has Anticorruption an
not impact situation continue before, closely. the to said I've As monitor far, seeing we any are thus we and
for are we understand to in is summary, lag But China watching that's expected and business us for forward. are installation we will extent In is reagent of that create on a expecting. instruments to moving purchased driver what growth rates weeks a For the few example, be ring. our this fine
As I said, we're bullish.
up in QX, expect we quarter, be now growth to expect business XX% our and over units. XXXX. For prior Shifting continued we X year the to
regions, Pacific, Africa is China, we revenue increased leading durability. America, business our growth lab year-over-year with unit in where Our delivered saw geographic East of versus business Asia all which indicator nonrespiratory lapse placements XX% XXXX, Europe, including growth and and across North Middle the major growth X% year-to-date and
pleased now instrument driven The the returning the primed placements few demand labs to -- our our in note increased to clinical be utilization forward. with customer levels meet backlog we chemistry instrument notable strength integrated to also that majority have strong continues by years. manufacturing levels to worked return a and to the over pre-pandemic output of last normalized I'm and moving through
our lapse the Additionally, and well trend automation that base installed that positive and and also a recurring trend the system, since portends launching integrated seen increased year-over-year, we've future. XX% integrated Vitros-XTXXXX our XX% our grew in excellence revenue our for implementing program commercial continuing
the live, base significant going experience track automation. a expanding milestone system with reached through Finally, further and laboratory XXX our we footprint automation
cornerstone a its we response in critical to point-of-care acute COVID-XX to reflect RSV, role containing addition pandemic, a COVID-XX point-of-care strap And such range portfolio remains our flu, and care of virus. A. our the the in settings, public Turning on deadly this played spread role the as business for infections, managing a to in as I respiratory of
the over testing shots the X has necessity With booster away negative last the of and initial to from COVID-XX vaccine shift and asymptomatic a years, PCR launch test. the a there subsequent been produce
understanding their However, has greater responsibility spread. and the public for individual taken is virus how a health
volume from We are patients and seeing symptoms. influenza-like considerable illness
in de U.S. CLIA received FIA This novo plus antigen be Turning self-administer to awarded waiver in detects over asking COVID-XX the clinic, the first to testing we COVID-XX their COVID-XX the that SARS report in our delighted their for leader our antigen doctor clients our QuickVue market for is agencies or a capabilities. X the FDA the further through test September. that in to test as strengthening rapid medicine process. test at-home position new cabinet counter to I'm Sofia
CLIA a now antigen receive is to This also first waiver. the rapid test
impact were with fourth line XXXX we at will commences households. addition the award to tests the is award XX was million a to quarter top waiver, in In impact months provided will results, to to make financial our over $XX to on providing continue that guidance. this the financial while in to and from U.S. our be feel included not the privileged we COVID-XX COVID-XX test American The to material to receive our our free the CLIA and home government And provide government. expected continue from government honored U.S. not award for an
help for moved to into government another state. so, has We clearly doing can an pandemic the doing level COVID-XX believe be what endemic by threat. we're prepared we
expect respiratory persistent to However, many we years pathogen for to it come. a remain
both informed Our testing be and capabilities to accurately. allow patients and providers quickly
XX% portfolio, medicine the X%. and transfusion the expectations hematology business met grew of represents our and our medicine Our transfusion approximately for business. immuno which quarter
in on The Molecular and viruses. our R&D team and bloodstream multiple recognize panels responsible increasing role pathogens our Diagnostics that GI around and play I to infections nervous tract patient. and launched can more are solutions early the am testing they the I be lastly, we to -- workflow to for generated for its consider is very public time circulating that frame of year. syndromic syndromic like relevant Savanna incorrectly multiplex as closer system. critical. of allowing rapid awareness simple a the thereafter. the pioneers treatment. in and important Savannah instrument central information confident this U.S. detecting need affect and the quickly And system, of Savannah clinically rise can flexibility, panels accurate respiratory test Unique With by potential diagnostic business, clearance the will syndromic fast, commercially time receive end in the
that We pace. have I instrument at we will expect launch inventory, and
focused clinical those and continue we we needs. differentiate ourselves in the that to innovate on address are developing As unmet and significantly market, assays panels
for the underestimated this. help of numbers this example since how of just test compounds devastating, newborns this And a we As bacterial fastest-growing is have but those surged unique combat panel. to have treatable diagnostic are of sufficient And a XX% cases, of easily XXX% provide those STI one with because syphilis methods problem. increase. primary solutions diagnostic cases to in infections. The testing with Again, STIs can one is likely an among added lack syphilis XXXX. example, increase our Syphilis
and We well. to planned to expect novo panels several differentiated de be be as
complexity While we to our than aggressively in on on next test and rooted XX business, our allocation expand agile experience chain products suite and months today operational upgrading Ortho and with stead capabilities, our portfolio culture, integration, and nearly we continue of are driving create Quidel phase focused more did our enhancing becoming reducing global supply we capital and efficient, of highly the management into a organization and improving manufacturing previously know are operations to capabilities. we
other These we cost efforts create on business also P&L growth can so increase and investments. reductions room our that development our
is $XXX capture and incremental lockstep synergies in a improve it's on quarter the prioritizing efficiency long-term that to with creating and call, I years increase drive can our being help in second million worth As X mentioned our cost over work repeating, underway, and well is mindset growth profitability. done initiatives growth,
these EPS our are FX we than companies concerned headwinds, and inflation about offset effects can synergy more in ultimately other efforts cost While growth. and believe result
products solving colleagues complex the to me bring I thank and turn many innovation who a our take to patients let my issues moment Before call over to Joe, from to brilliant stakeholders complex the believe most a in who providers put to our world. advance to to the vision when matters around their who our trust accuracy healthier our diagnostics investors in power future for patients
meet care to apart. the to QuidelOrtho the turn over call Joe? quickly ability what our to us at financial health and proven ever-changing review close needs sets XXXX. let's is Joe guidance performance that, to of With
